drugset / Trial / NCT01331590
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the ability of G-CSF to disrupt the bone marrow microenvironment as a means to increase the efficacy of chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
Timeline
- Start
- 2011-07
- Primary completion
- 2014-10
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G-CSF | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | 2660 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 5 mg/m2 | Oral |
| Background | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 3330 mg/m2 | Intravenous |